Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).

Feature | Structural Heart

TAVR Access is Inequitable Based Socioeconomics Level and Geography

April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United ...

April 30, 2021

The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.

Feature | Cardiogenic Shock | By Dave Fornell, Editor

National Cardiogenic Shock Initiative Protocol Shows 71 Percent Survival

April 29, 2021 — The results of a large, national heart attack study show that patients with cardiogenic shock survived ...

April 29, 2021

The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.

News | Radial Access | Dave Fornell, Editor

Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

April 28, 2021

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images

News | Cath Lab

COVID Caused Major Decline in Heart Attack Patients Seeking Care

April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular ...

April 28, 2021

A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab

SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document

April 28, 2021 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus ...

April 28, 2021

Sponsored Content | Webinar | Structural Heart

WEBINAR: 3-D Multi-planar Imaging to Enhance Ultrasound Guidance of Interventional Cardiac Procedures

This on-demand webinar teaches viewers how new multi-planar imaging techniques such as Cardiac MultiVue and TrueVue make ...

April 26, 2021

Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

News | Heart Failure

Socioeconomic Disparities Associate With Epigenetics and Heart Failure Outcomes

April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure disproportio ...

April 26, 2021

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Feature | Structural Heart

Advice For Hospitals Starting a Structural Heart Program

The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural ...

April 22, 2021

The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.

News | Hemostasis Management

FDA Clears SiteSeal SV Vascular Closure Device for the Brachial Arteries

April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market ...

April 21, 2021

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart

Creating a Structural Heart Program is an Investment in the Future of the Hospital

As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon ...

April 21, 2021

The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders

Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

April 20, 2021

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.

News | Atrial Fibrillation

Gene Therapy for Atrial Fibrillation Will Be Investigated With $3.67 million NIH Grant

April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm ...

April 19, 2021

The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal transseptal crossing devices. This is the only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ own suite of sheaths and with sheaths sold by other manufacturers.

News | EP Lab

FDA Clears Acutus Medical AcQCross Suite of Transseptal Crossing Devices

April 14, 2021 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal ...

April 14, 2021

The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR).

News | Structural Heart

Abbott Receives CE Mark and Canadian Approval for Next-Generation TriClip Tricuspid Valve Repair Device

April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for ...

April 08, 2021

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

News | Stroke

Thrombectomy Market Will Grow With Newly Approved Adjustable Stent Retriever

April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices), sh ...

April 07, 2021